Ten-year survival of the cemented MS-30 femoral stem: increased revision rate in male patients.
This retrospective study evaluated the clinical and radiographic results of 337 consecutive matte surfaced, straight cemented MS-30 femoral stems implanted with first -to second-generation cementing technique. The median age of the patients at time of surgery was 72 (27-91) years. The median duration of follow-up was 10 (0.1-14) years. A Kaplan Meier survival analysis was performed. At follow-up, 113 patients (120 stems) had died and 13 (13 hips) were lost to follow-up. Twenty-one hips had undergone femoral revision, 13 for aseptic loosening, five for infection, two for dislocation and one for periprosthetic fracture. Survival analysis with revision of the femoral component for any reason as the end point was 91% (95% CI: 87-96) and for aseptic loosening 94% (95% CI: 90-97) at 12 years. Females (n = 245) with 99% (95% CI: 97-100) had significantly better survival compared to males (n = 92) showing 80% stem survival (95% CI: 67-91) at 12 years (p < 0.001). Median Harris Hip score (HHS) was 82 (25-100) points. Male patients had a higher activity score than female patients (p = 0.04). Femoral Dorr type A was associated with a higher risk of failure. THA with the MS-30 stem revealed satisfactory midterm results despite relatively crude cementing techniques. However, the higher revision rate in males and Dorr Type A is of concern.